A Phase 3, Randomized, Controlled Trial of Resmetirom in NASH with Liver Fibrosis
Open accessThe DOI matches its Crossref record; 26 of the 26 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Nonalcoholic steatohepatitis (NASH) is a progressive liver disease with no approved treatment. Resmetirom is an oral, liver-directed, thyroid hormone receptor beta-selective agonist in development for the treatment of NASH with liver fibrosis. METHODS: We are conducting an ongoing phase 3 trial involving adults with biopsy-confirmed NASH and a fibrosis stage of F1B, F2, or F3 (stages range from F0 [no fibrosis] to F4 [cirrhosis]). Patients were randomly assigned in a 1:1:1 ratio to receive once-daily resmetirom at a dose of 80 mg or 100 mg or placebo. The two primary end points at week 52 were NASH resolution (including a reduction in the nonalcoholic fatty liver disease [NAFLD] activity score by ≥2 points; scores range from 0 to 8, with higher scores indicating more severe disease) with no worsening of fibrosis, and an improvement (reduction) in fibrosis by at least one stage with no worsening of the NAFLD activity score. RESULTS: Overall, 966 patients formed the primary analysis population (322 in the 80-mg resmetirom group, 323 in the 100-mg resmetirom group, and 321 in the placebo group). NASH resolution with no worsening of fibrosis was achieved in 25.9% of the patients in the 80-mg resmetirom group and 29.9% of those in the 100-mg resmetirom group, as compared with 9.7% of those in the placebo group (P<0.001 for both comparisons with placebo). Fibrosis improvement by at least one stage with no worsening of the NAFLD activity score was achieved in 24.2% of the patients in the 80-mg resmetirom group and 25.9% of those in the 100-mg resmetirom group, as compared with 14.2% of those in the placebo group (P<0.001 for both comparisons with placebo). The change in low-density lipoprotein cholesterol levels from baseline to week 24 was -13.6% in the 80-mg resmetirom group and -16.3% in the 100-mg resmetirom group, as compared with 0.1% in the placebo group (P<0.001 for both comparisons with placebo). Diarrhea and nausea were more frequent with resmetirom than with placebo. The incidence of serious adverse events was similar across trial groups: 10.9% in the 80-mg resmetirom group, 12.7% in the 100-mg resmetirom group, and 11.5% in the placebo group. CONCLUSIONS: Both the 80-mg dose and the 100-mg dose of resmetirom were superior to placebo with respect to NASH resolution and improvement in liver fibrosis by at least one stage. (Funded by Madrigal Pharmaceuticals; MAESTRO-NASH ClinicalTrials.gov number, NCT03900429.).
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source doesn’t support the claim as written.
In the citing paper
“Therefore, incretinbased medications for the treatment of MASLD could be made available, supplementing resmetirom as the only approved medication in the USA and Europe.87”
From GLP-1 receptor agonists and next-generation incretin-based medications: metabolic, cardiovascular, and renal benefits (2026) · cites this paper as [87]
Checked by a reasoning model — may be wrong.
Experimental — accuracy not yet measuredThe cited source doesn’t support the claim as written.
In the citing paper
“Resmetirom is the first compound approved for the treatment of MASH in conjunction with diet and exercise, showing the importance of combining lifestyle changes to pharmacological treatment.91”
From Lipid metabolism in MASLD and MASH: From mechanism to the clinic (2024) · cites this paper as [91]
Checked by a reasoning model — may be wrong.
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“It was not until March 2024 that the U.S. Food and Drug Administration (FDA) approved the first drug, Rezdiffra, for non-alcoholic steatohepatitis (NASH) with liver fibrosis.”
From Mechanisms, efficacy, and future perspectives of cellular-based therapies for liver fibrosis/cirrhosis: focusing on mesenchymal stromal cells (2025) · cites this paper as [8]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Resmetirom, a THRβ agonist, showed antisteatogenic potential in a 36-week phase 2 RCT in people with biopsy-confirmed MASH and fibrosis, accompanied by a rise in circulating adiponectin and improved plasma lipid profile [210,211].”
From Obesity and MASLD: Is weight loss the (only) key to treat metabolic liver disease? (2024) · cites this paper as [211]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“About 14% of participants in the MAESTRO-NASH trial were on GLP1RA treatment, with stable dosage in the 6 months and stable body weight in the 3 months preceding screening liver biopsy.”
From EASL-EASD-EASO Clinical Practice Guidelines on the management of metabolic dysfunction-associated steatotic liver disease (MASLD). (2024) · cites this paper as [350]
Experimental — accuracy not yet measured
20 more claims about this paper
Create a free account to see every claim other papers make about this one.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Design and validation of a histological scoring system for nonalcoholic fatty liver disease†
Kleiner, D. E., Brunt, E. M., Van Natta, M., Behling, C., Contos, M. J., Cummings, O. W., Ferrell, L. D., Liu, Y., Torbenson, M. S., Unalp‐Arida, A., et al. (2005) · Hepatology · doi:10.1002/hep.20701 · Cited by 10,791
Self-citationMach, F., Baigent, C., Catapano, A. L., Koskinas, K. C., Casula, M., Badimon, L., Chapman, M. J., De Backer, G. G., Delgado, V., Ference, B. A., et al. (2020) · European Heart Journal · doi:10.1093/eurheartj/ehz455 · Cited by 8,961
Chalasani, N., Younossi, Z., Lavine, J. E., Charlton, M., Cusi, K., Rinella, M., Harrison, S. A., Brunt, E. M., & Sanyal, A. J. (2018) · Hepatology · doi:10.1002/hep.29367 · Cited by 7,239
Self-citationAlberti, K. G. M. M., Zimmet, P., & Shaw, J. (2006) · Diabetic Medicine · doi:10.1111/j.1464-5491.2006.01858.x · Cited by 6,597
2013 ACC/AHA Guideline on the Assessment of Cardiovascular Risk
Goff, D. C., Lloyd-Jones, D. M., Bennett, G., Coady, S., D’Agostino, R. B., Gibbons, R., Greenland, P., Lackland, D. T., Levy, D., O’Donnell, C. J., et al. (2014) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2013.11.005 · Cited by 4,945
A multisociety Delphi consensus statement on new fatty liver disease nomenclature
Rinella, M. E., Lazarus, J. V., Ratziu, V., Francque, S. M., Sanyal, A. J., Kanwal, F., Romero, D., Abdelmalek, M. F., Anstee, Q. M., Arab, J. P., et al. (2023) · Hepatology · doi:10.1097/hep.0000000000000520 · Cited by 3,476
Self-citationAngulo, P., Kleiner, D. E., Dam-Larsen, S., Adams, L. A., Bjornsson, E. S., Charatcharoenwitthaya, P., Mills, P. R., Keach, J. C., Lafferty, H. D., Stahler, A., et al. (2015) · Gastroenterology · doi:10.1053/j.gastro.2015.04.043 · Cited by 2,987
Rinella, M. E., Neuschwander-Tetri, B. A., Siddiqui, M. S., Abdelmalek, M. F., Caldwell, S., Barb, D., Kleiner, D. E., & Loomba, R. (2023) · Hepatology · doi:10.1097/hep.0000000000000323 · Cited by 2,667
Self-citationEstes, C., Razavi, H., Loomba, R., Younossi, Z., & Sanyal, A. J. (2018) · Hepatology · doi:10.1002/hep.29466 · Cited by 2,399
Self-citationMechanisms and disease consequences of nonalcoholic fatty liver disease
Loomba, R., Friedman, S. L., & Shulman, G. I. (2021) · Cell · doi:10.1016/j.cell.2021.04.015 · Cited by 2,002
Self-citation
Research works printed but not linked: 2
- 24. Conduct of clinical trials of medical products during the COVID-19 public health emergency: guidance for industry, investigators, and institutional review boards. Silver Spring, MD: Food and Drug Administration, August 30, 2021 (https:// www . fda . gov/ media/ 136238/ download/ ). Goff DC Jr, Lloyd-Jones DM, Bennett G, et al. 2013 ACC/AHA guideline on the
- 3. ogy/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol 2014; 63: 2935-59.
Cited by
Items 401–500 of 1,003
Widowati, W., Sabrina, A. H. N., Sutendi, A. F., Zahiroh, F. H., Nurjamil, A. M., Wargasetia, T. L., Nainggolan, I. M., Azis, R., Rismani, E., & Vosough, M. (2026) · Journal of Immunology Research · doi:10.1155/jimr/2656395 · Cited by 18
“Recently, resmetirom, a thyroid hormone receptor β -selective agonist, has demonstrated promising results in reducing liver fat and improving fi brosis biomarkers in nonalcoholic steatohepatitis (NASH), positioning it as a potential therapeutic for liver fi brosis management [86].”
Noureddin, M., Kowdley, K. V., Odrljin, T. M., Bain, G., Zhao, J., Jeglinski, B. I., Koziel, M. J., & Loomba, R. S. (2026) · The Lancet · doi:10.1016/s0140-6736(25)02276-7 · Cited by 20
Self-citationQiu, Y., Laguna, J. C., Alegret, M., & Vilà, L. (2026) · Nutrients · doi:10.3390/nu18040679 · Cited by 16
“In clinical trials, resmetirom showed significant improvements in NASH resolution and fibrosis reduction in about 25–30% of treated patients, indicating that not all patients respond adequately [17].”
The many pathways driving liver inflammation in MASH
Tilg, H., Adolph, T. E., Romeo, S., & Loomba, R. S. (2026) · Cell Metabolism · doi:10.1016/j.cmet.2026.02.018 · Cited by 20
Self-citationWang, Y., He, Y., Sun, W., Yu, H., Tao, W., Yu, X., Jia, D., Liu, Y., Pandol, S. J., & Li, L. (2024) · Drugs · doi:10.1007/s40265-024-02015-6 · Cited by 18
Pugliese, N., Polverini, D., Lombardi, R., Pennisi, G., Ravaioli, F., Armandi, A., Buzzetti, E., Dalbeni, A., Liguori, A., Mantovani, A., et al. (2024) · Journal of Personalized Medicine · doi:10.3390/jpm14060568 · Cited by 21
Nicotinate-curcumin improves NASH by inhibiting the AKR1B10/ACCα-mediated triglyceride synthesis
Lin, X.-L., Zeng, Y., Ning, J., Cao, Z., Bu, L.-L., Liao, W.-J., Zhang, Z., Zhao, T.-J., Fu, R.-G., Yang, X., et al. (2024) · Lipids in Health and Disease · doi:10.1186/s12944-024-02162-5 · Cited by 20
“However, the safety profile of OCA necessitates further investigation, and currently, there is only approved resmetirom as the world’s first drug for treating NASH, and still has approved drugs for NASH halting the transition from NAFLD to NASH [50, 51].”
BackgroundZhang, Z., Wang, H., & Chen, Y. (2024) · Frontiers in Nutrition · doi:10.3389/fnut.2024.1412516 · Cited by 16
Kendall, T. J., Chng, E., Ren, Y., Tai, D., Ho, G., & Fallowfield, J. A. (2024) · Liver International · doi:10.1111/liv.16062 · Cited by 17
“Furthermore, despite years of trying, there is only one licensed treatment for MASH (in patients with moderate to advanced fibrosis), 5 and many candidate drugs have failed in late-phase clinical trials.”
Kawanaka, M., Kamada, Y., Takahashi, K., Iwaki, M., Nishino, K., Zhao, W., Seko, Y., Yoneda, M., Kubotsu, Y., Fujii, H., et al. (2024) · Gastro Hep Advances · doi:10.1016/j.gastha.2024.08.008 · Cited by 19
Fishman, J., Kim, Y., Parisé, H., Bercaw, E., & Smith, Z. (2024) · Journal of Medical Economics · doi:10.1080/13696998.2024.2393952 · Cited by 15
“Costs related to the management of common adverse events (AEs) associated with resmetirom (i.e. diarrhea and nausea) were included in a sensitivity analysis, given that these events were transitory in nature 17 .”
InfluentialTargeting ketone body metabolism to treat fatty liver disease
Kwon, S., Jeyaratnam, R., & Kim, K.-H. (2024) · Journal of Pharmacy & Pharmaceutical Sciences · doi:10.3389/jpps.2024.13375 · Cited by 18
The Changing Demographics and Epidemiology of Hepatocellular Carcinoma
Gujarathi, R., Klein, J. A., Liao, C., & Pillai, A. A. (2024) · Clinics in Liver Disease · doi:10.1016/j.cld.2024.08.001 · Cited by 18
A Pragmatic Management Approach for Metabolic Dysfunction-Associated Steatosis and Steatohepatitis
Shah, N., & Sanyal, A. J. (2024) · The American Journal of Gastroenterology · doi:10.14309/ajg.0000000000003215 · Cited by 17
Self-citationMedical treatment of primary sclerosing cholangitis: What have we learned and where are we going?
Karlsen, T. H., Jørgensen, K. K., & Bergquist, A. M. (2024) · Hepatology · doi:10.1097/hep.0000000000001172 · Cited by 19
“[132] With its unequal manifestations throughout the biliary tree, liver biopsy findings in PSC are often unevenly distributed, with a mixture of late-stage and early-stage lesions even being found in the same liver.”
Liu, C., Zeng, Q., Hu, T., Huang, Y., Song, Y., Guan, H., Rockey, D. C., Tang, H. C., & Li, S. (2025) · Portal hypertension & cirrhosis · doi:10.1002/poh2.100 · Cited by 15
Bril, F., Berg, G. A., Barchuk, M., & Nogueira, J. P. (2025) · Journal of Lipid and Atherosclerosis · doi:10.12997/jla.2025.14.1.5 · Cited by 17
Koda, Y., & Nagasaki, Y. (2024) · Journal of Controlled Release · doi:10.1016/j.jconrel.2024.04.050 · Cited by 17
Cho, S. W. (2024) · Endocrinology and Metabolism · doi:10.3803/enm.2024.203 · Cited by 16
“Most recently, the 52-week results of the ongoing phase 3 MAESTRO-NASH trial (NCT03900429) have been presented [7].”
BackgroundA turning point in hepatology? EASL reflects on the first approved drug for MASH
Francque, S., Krag, A. A., Shawcross, D. L., & Zelber‐Sagi, S. (2024) · Journal of Hepatology · doi:10.1016/j.jhep.2024.04.036 · Cited by 16
Self-citationZhu, J., Liao, X., Du, L., Lv, P., & Deng, J. K. (2024) · Frontiers in Endocrinology · doi:10.3389/fendo.2024.1426103 · Cited by 16
Wong, S. W., Yang, Y., Chen, H., Xie, L. H., Shen, X., Zhang, N., & Wu, J. H. (2025) · Acta Pharmacologica Sinica · doi:10.1038/s41401-024-01466-7 · Cited by 14
Zhang, Y. L., Yang, J., Min, J., Huang, S. H., Li, Y., & Liu, S. (2025) · Journal of Translational Medicine · doi:10.1186/s12967-025-06255-2 · Cited by 18
“Although resatinib, the first FDA-approved drug for the treatment of MASH, has been successfully marketed, it is not able to meet clinical needs [235].”
Estrogen receptor 1 signaling in hepatic stellate cells designates resistance to liver fibrosis
Li, T., Wang, G., Zhao, H., Liu, F., Deng, Z., Chen, D., Zhou, X., Cao, Y., Fu, W., Zhang, H., et al. (2025) · Cell Discovery · doi:10.1038/s41421-025-00783-3 · Cited by 20
Targeting Metabolism: Innovative Therapies for MASLD Unveiled
Wang, W., Gao, X., Niu, W., Yin, J., & He, K. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26094077 · Cited by 15
LEADS – a comprehensive human liver-on-a-chip for non-alcoholic steatohepatitis (NASH) drug testing
Balachander, G. M., Ng, I. C., Pai, R. R., Mitra, K., Tasnim, F., Lim, Y. S., Kwok, R., Song, Y., Yaw, L. P., Quah, C. B., et al. (2025) · Lab on a Chip · doi:10.1039/d5lc00221d · Cited by 17
Xiao, T., Liu, H., Tian, N., Lian, L., Miao, K., Li, Y., Chen, L., Yuan, H., Du, M., Wu, S., et al. (2025) · Liver International · doi:10.1111/liv.70208 · Cited by 14
“Resmetirom has been recently approved by the FDA for the treatment of adults with noncirrhotic metabolic dysfunction-associated steatohepatitis (MASH) and moderate- to-advanced fibrosis and has the additional benefit of reducing Lp(a) [13].”
Franck, M., John, K., Rau, M., Geier, A., Sowa, J., Schattenberg, J. M., Demir, M., Wedemeyer, H. H., Schulze‐Osthoff, K., & Bantel, H. (2025) · Liver International · doi:10.1111/liv.70281 · Cited by 18
Self-citationOsta, E., Rios, F. S., Jaganathan, S., Thomas, C., Tsai, E., Surabhi, V. R., Prasad, S. R., & Katabathina, V. S. (2025) · Radiographics · doi:10.1148/rg.240221 · Cited by 16
Zhou, H., Huang, Y., Chen, C., Song, M., & Hylemon, P. B. (2026) · Pharmacological Reviews · doi:10.1016/j.pharmr.2026.100120 · Cited by 19
Grocic, M., Nguyen, M., & Sanyal, A. J. (2026) · Diabetes Obesity and Metabolism · doi:10.1111/dom.70662 · Cited by 19
“Resmetirom showed improvement in MASH resolution and fibrosis regression compared to placebo, despite not causing weight loss or improvement in insulin resistance [87, 88].”
Self-citationPotential Therapeutic Targets in Obesity, Sleep Apnea, Diabetes, and Fatty Liver Disease
Gu, C., Bernstein, N., Mittal, N., Kurnool, S., Schwartz, H. R., Loomba, R. S., & Malhotra, A. (2024) · Journal of Clinical Medicine · doi:10.3390/jcm13082231 · Cited by 16
“There are few U.S. Food and Drug Administration-approved drugs that exist to treat MASLD [75], and the mainstay of therapy continues to focus on lifestyle interventions targeting dietary changes and weight loss.”
BackgroundSelf-citationWang, J.-J., Zheng, Z., & Zhang, Y. (2024) · Journal of Inflammation Research · doi:10.2147/jir.s466469 · Cited by 14
Emerging mechanisms of non-alcoholic steatohepatitis and novel drug therapies
Hao, C. H. E. N., Zhou, Y., Hao, H., & XIONG, J. (2024) · Chinese Journal of Natural Medicines · doi:10.1016/s1875-5364(24)60690-4 · Cited by 23
Fatty Liver Disease Along Cushing Syndrome Evolution
Marengo, M., Briet, C., Munier, M., Boursier, J., Rodien, P., & Suteau, V. (2024) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgae568 · Cited by 16
Pathogenic role of acyl coenzyme A binding protein (ACBP) in Cushing’s syndrome
Pan, H., Tian, A.-L., Chen, H., Xia, Y., Sauvat, A., Moriceau, S., Lambertucci, F., Motiño, O., Zhao, L., Liu, P., et al. (2024) · Nature Metabolism · doi:10.1038/s42255-024-01170-0 · Cited by 14
“We therefore resorted to the selective thyroid hormone receptor β (THR-β) agonist resmetirom (RES), which has been approved by the Food and Drug Administration (FDA) for the treatment of non-alcoholic steatohepatitis 39 .”
Tian, C., Deng, S., Zhang, Z., Zheng, K., & Wei, L. (2025) · Life Sciences · doi:10.1016/j.lfs.2025.123557 · Cited by 17
Recent advances in targeting obesity, with a focus on TGF-β signaling and vagus nerve innervation
John, S., Bhowmick, K., Park, A., Huang, H., Yang, X., & Mishra, L. (2025) · Bioelectronic Medicine · doi:10.1186/s42234-025-00172-x · Cited by 15
“This review explores the intersection of TGF-β signaling, neural regulation, and metabolic disorders in the context of obesity, MASLD, MASH, and HCC. Advances in mouse models and human trials will continue to inform strategies for modulating TGF-β and neural pathways, offering hope for treatments targeting the metabol…”
InfluentialAllen, A. M., Lazarus, J. V., Alkhouri, N., Noureddin, M., Wong, V. W., Tsochatzis, E. A., de Avila, L., Racila, A., Nader, F., Mark, H. E., et al. (2025) · Hepatology Communications · doi:10.1097/hc9.0000000000000678 · Cited by 16
“[12] The discrepancy between this cutoff and the use of an 8 kPa cutoff in the other guidelines could potentially cause confusion by creating Thisstudy ’ s strengths include its global scope and detailed examination of MASLD care pathways, high-lighting gaps in current practice and identifying…”
Self-citationBarritt, A. S., Tapper, E. B., Newsome, P. N., Gazis, D. R., Morris, H., Mospan, A. R., Perez, A. D., Kim, Y., Neuschwander‐Tetri, B. A., Loomba, R. S., et al. (2025) · The American Journal of Gastroenterology · doi:10.14309/ajg.0000000000003595 · Cited by 16
Self-citationIs There a Diagnostic Miracle on the Horizon? Emerging Biomarkers in MASLD
Iwaszko-Sochal, K., Kasztelan‐Szczerbińska, B., & Cichoż‐Lach, H. (2025) · Journal of Clinical Medicine · doi:10.3390/jcm14176148 · Cited by 14
“The phase III MAESTRO-NASH trial demonstrated its superiority over placebo at doses of 80 and 100 mg [31,32].”
The multifaceted effects of semaglutide: exploring its broad therapeutic applications
Alkhatib, M., Almasri, N., Alshwayyat, S., Almahariq, H., Hammadeh, B. M., Taimeh, Z., Alkhatib, L., Alshwayat, A. R. I., Saadeh, N. A., & Al‐kurdi, M. A. (2025) · Future Science OA · doi:10.1080/20565623.2025.2483607 · Cited by 17
“Semaglutide is a promising treatment for NASH [46], with resmetirom being the only FDA-approved drug specifically for NASH with fibrosis [47]. clinical trials have shown that semaglutide can reduce and even resolve NASH without cirrhosis, improving histological hepatic conditions, lobular…”
Imeglimin ameliorates MASLD by targeting PEN2 to activate AMPK pathway
Li, J., Zhang, R., Zeng, X. Y., Xu, W., Gao, L., He, S., Bingbing, W., Ma, Y., Nie, Y., Shirakawa, J., et al. (2025) · Metabolism · doi:10.1016/j.metabol.2025.156458 · Cited by 12
SOUZA, M. M. X. D., Al‐Sharif, L., Antunes, V., Wong, S. Y., Huang, D. Q., & Loomba, R. S. (2026) · Alimentary Pharmacology & Therapeutics · doi:10.1111/apt.70565 · Cited by 13
“Resmetirom, a liver-directed thyroid hormone receptor beta-selective agonist approved for F2/F3 MASH [15], has emerged as a candidate of interest in this setting.”
Self-citationWang, Y., Liu, C., Yang, Y., Zhang, L. R., Guo, X., Niu, C., Zhang, N., Ding, J., & Wu, J. H. (2024) · The FASEB Journal · doi:10.1096/fj.202400573rr · Cited by 13
“1,14,15 18 Sequencing techniques, such as metagenomics, have brought large groups of unknown microbial strains to light.”
Breakthrough in the Treatment of Metabolic Associated Steatotic Liver Disease: Is it all over?
Petroni, M. L., Perazza, F., & Marchesini, G. (2024) · Digestive and Liver Disease · doi:10.1016/j.dld.2024.04.021 · Cited by 14
Tincopa, M. A., & Loomba, R. S. (2024) · Seminars in Liver Disease · doi:10.1055/s-0044-1788277 · Cited by 15
Self-citationAlkhouri, N., McCarthy, D., Bayne, A.-C. V., Blonquist, T., Yurko‐Mauro, K., Vuppalanchi, R., Lawitz, E., & Chalasani, N. (2024) · Alimentary Pharmacology & Therapeutics · doi:10.1111/apt.18149 · Cited by 12
“8,9 Vitamin E is an antioxidant, an inhibitor of lipid peroxidation, and can modulate intracellular signalling molecules, for example, protein kinase C and nicotinamide adenine dinucleotide phosphate (NADPH) oxidase.”
Self-citationKoch, V., Gotta, J., Chernyak, V., Cengiz, D. S., Torgashov, K., Eichler, K., Vilgrain, V., Martin, S. S., Ziegengeist, N. S., Konrad, P., et al. (2024) · Journal of Magnetic Resonance Imaging · doi:10.1002/jmri.29560 · Cited by 14
Levien, T. L., & Baker, D. E. (2024) · Hospital Pharmacy · doi:10.1177/00185787241278571 · Cited by 15
Sex differences in murine MASH induced by a fructose-palmitate-cholesterol-enriched diet
Arivazhagan, L., Delbare, S., Wilson, R. A., Manigrasso, M. B., Zhou, B., Ruiz, H. H., Mangar, K., Higa, R., Brown, E., Li, H., et al. (2024) · JHEP Reports · doi:10.1016/j.jhepr.2024.101222 · Cited by 20
Anastasiou, G., Stefanakis, K., Hill, M. A., & Mantzoros, C. S. (2024) · Metabolism · doi:10.1016/j.metabol.2024.156044 · Cited by 12
Allen, A. M., Arab, J. P., & Wong, V. W. (2024) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/s41575-024-00990-5 · Cited by 16
“The antifibrotic effects of the only liver-specific drug (resmetirom) are encouraging but occur in only 25% of patients (11% response when adjusted for placebo effect) 13 .”
Scoparone alleviates nonalcoholic fatty liver disease by modulating the PPARα signaling pathway
Huang, P., Yang, L., Liu, T., Jiang, Y., Chen, Z., Song, H., & Zheng, P. (2024) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2024.177033 · Cited by 16
Aleman, J., Ravikumar, K., Wiegand, C., Schurdak, M. E., Vernetti, L. A., Gavlock, D. C., Reese, C. E., DeBiasio, R., LaRocca, G., Angarita, Y. D., et al. (2024) · Communications Biology · doi:10.1038/s42003-024-07006-7 · Cited by 14
The future of complement therapeutics
Kolev, M. V., Rao, K. N., Yeh, M. W., Parikh, A., & Deschatelets, P. (2024) · Exploration of Immunology · doi:10.37349/ei.2024.00161 · Cited by 15
Zong, J., Li, Y., Zhou, W., Mao, M., Xu, X., Cai, S., Li, M., & Ding, K. (2024) · International Journal of Biological Macromolecules · doi:10.1016/j.ijbiomac.2024.137936 · Cited by 15
Li, F., Yuan, R., Zhang, J., Su, B., & Qi, X. (2025) · Asian Journal of Pharmaceutical Sciences · doi:10.1016/j.ajps.2025.101025 · Cited by 18
“The limited diagnostic accuracy of existing non-invasive testing criteria may lead to misclassification, potentially resulting in over-or under-treatment with resmetirom [ 14 ,15 ,17 ].”
Mohammed, S., Ohene-Marfo, P., Jiang, C. Y., Peng, Z., Thadathil, N., Tran, A., Nicklas, E. H., Bhaskaran, S., Wang, D., Selvarani, R., et al. (2025) · GeroScience · doi:10.1007/s11357-025-01553-5 · Cited by 12
“Despite many clinical trials, resmetirom remains the only FDA-approved drug for MASH (March 2024) [11], underscoring the need to better understand MASLD/ MASH pathogenesis in aging.”
Macrophage-specific PHGDH protects against MAFLD by suppressing TAK1
Hu, P., Shan, X., Dong, H., Yu, S., Wang, B., Xiong, H., Ji, Z., Jing, W., Cui, Y., Li, Z., et al. (2025) · Cell Reports · doi:10.1016/j.celrep.2025.115426 · Cited by 12
Bansal, B., Lajeunesse‐Trempe, F., Keshvani, N., Lavie, C. J., & Pandey, A. (2025) · Canadian Journal of Cardiology · doi:10.1016/j.cjca.2025.04.012 · Cited by 28
Liu, C., & Liu, C. (2025) · Journal of Obesity & Metabolic Syndrome · doi:10.7570/jomes25028 · Cited by 18
Constructing biomimetic microenvironments for liver regeneration
(2025) · doi:10.1186/s12951-025-03729-9 · Cited by 11
“Cirrhosis develops as an advancing hepatic disorder resulting from multiple etiologies, characterized by significant changes in liver architecture and gradual loss of liver function [113, 114].”
Targeting Polymeric Nanoparticles to Specific Cell Populations in the Liver
Harkins, L., Vilarinho, S., & Saltzman, W. M. (2025) · Biochemistry · doi:10.1021/acs.biochem.4c00712 · Cited by 12
Suppressing MASH fibrotic progression by blocking succinate-GPR91 signaling in HSCs
Xie, L., Chen, H., Zhang, L., Yang, Y., Zhou, Y., Ma, Y., Liu, C., Wang, Y.-L., Zhu, Q., Yan, Y.-J., et al. (2025) · Hepatology · doi:10.1097/hep.0000000000001405 · Cited by 16
Tang, X., Zhou, Y., Xia, L., Lin, X., Zhu, Y., Chen, M., Wang, J., & Li, Y. (2025) · Molecules · doi:10.3390/molecules30153066 · Cited by 13
“Resmetirom, a selective agonist of the thyroid hormone receptor-β (THR-β ), demonstrates therapeutic potential by modulating hepatic and systemic lipid metabolism [154].”
Dunn, N., Verma, N., & Dunn, W. (2025) · Journal of Clinical and Experimental Hepatology · doi:10.1016/j.jceh.2025.103184 · Cited by 17
Jin, J., Cheng, K., Chen, M., Liang, H., & Zhang, W. (2025) · International Journal of Biological Sciences · doi:10.7150/ijbs.117394 · Cited by 16
“Resmetirom currently represents the sole US Food and Drug Administration (FDA)-approved pharmacotherapy for MASLD, exerting therapeutic effects via selective thyroid hormone receptor activation [219].”
Luo, L., Shao, C., Teng, L., Zhuo, S., Dong, Z., Wang, W. J., Ye, J., & Zhong, B. (2025) · BMJ Open Gastroenterology · doi:10.1136/bmjgast-2025-001895 · Cited by 16
Florentino, R. M., Animasahun, O. H., Haep, N., Nenwani, M., Omoloja, K., Altay, L. N., Achreja, A., Morita, K., Motomura, T., Díaz‐Aragon, R., et al. (2025) · JCI Insight · doi:10.1172/jci.insight.193805 · Cited by 14
“Resmetirom, a thyromimetic engineered for selective activation of thyroid hormone receptor β in the liver, is the only approved drug therapy for the treatment of the disease (3).”
Management of Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD): Facts and Hopes
Adinolfi, L. E., Marrone, A., Izzi, A., & Craxì, A. (2025) · Journal of Clinical and Experimental Hepatology · doi:10.1016/j.jceh.2025.103411 · Cited by 11
Sanyal, A. J., Nakajima, A., Bugianesi, E., Sebastiani, G., Schattenberg, J. M., Adams, L. A., Noureddin, M., Yoneda, M., Bédossa, P., Younossi, Z. M., et al. (2025) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2025.12.001 · Cited by 18
Self-citationDecoding the CHI3L1/IL-13Rα2 signaling nexus in MASH-fibrosis pathogenesis
Zheng, Q., Cao, Y., Jiang, X., Wang, X., Wang, X., He, Y., Ma, W., Wu, H., Jiang, Y., WANG, T., et al. (2025) · Science Advances · doi:10.1126/sciadv.adz3223 · Cited by 14
Liver regeneration: unraveling the molecular mechanisms and clinical application
Wang, N., Guo, M.-H., Zhang, C., Jiang, R.-J., Bi, J., Sun, J., & Liu, B. (2025) · Journal of Translational Medicine · doi:10.1186/s12967-025-07412-3 · Cited by 13
“By reducing inflammation and inhibiting fibrosis, Resmetirom helps maintain the integrity and function of the liver structure [158].”
The Role of Galectin-3 in Liver Inflammation and Fibrosis
Lurje, I., Biegel, D. K., Zhang, I., & Tacke, F. (2026) · Journal of Inflammation Research · doi:10.2147/jir.s572637 · Cited by 16
Hénin, G., Loumaye, A., Deldicque, L., Leclercq, I. A., & Lanthier, N. (2024) · Liver International · doi:10.1111/liv.15938 · Cited by 12
“28,29 The pathophysiological mechanisms by which physical”
Self-citationMcGlone, E. R., Hope, D. C. D., Davies, I., Dore, M. H., Goldin, R. D., Jones, B. J., Liu, Z., Li, J. V., Vorkas, P. A., Khoo, B. C. E., et al. (2024) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2024.116888 · Cited by 13
Ahmed, M., & Ahmed, M. H. (2024) · Journal of Clinical Medicine · doi:10.3390/jcm13133893 · Cited by 13
Hermanson, J. B., Tolba, S. A., Chrisler, E. A., & Leone, V. (2024) · The Journal of Nutritional Biochemistry · doi:10.1016/j.jnutbio.2024.109704 · Cited by 14
Bittla, P., Paidimarri, S. P., Ayuthu, S., Chauhan, Y. D., Saad, M. Z., Mirza, A. A., & Khan, S. (2024) · Cureus · doi:10.7759/cureus.69919 · Cited by 11
Kovynev, A., Ying, Z., Zhang, S., Olgiati, E., Lambooij, J. M., Visentin, C., Guigas, B., Ducarmon, Q. R., Rensen, P. C. N., & Schönke, M. (2024) · Journal of Pineal Research · doi:10.1111/jpi.70003 · Cited by 13
“Liver steatosis and MASH are reversible, but pharmaceutical treatment options are currently limited, with the first anti ‐ MASLD treatment having been conditionally approved by the USA Food and Drug Administration only this year [5].”
Inhibition of CCl4-induced liver inflammation and fibrosis by a NEU3 inhibitor
Pilling, D., Martinez, T. C., & Gomer, R. H. (2024) · PLoS ONE · doi:10.1371/journal.pone.0308060 · Cited by 10
“Unfortunately, this drug is only effective in 30% of patients at reducing steatohepatitis (steatosis with inflammation), and only effective in 25% of patients at reducing fibrosis [6].”
Tang, M., Wang, X., Wang, S., Xing, C., Xu, Q., Mu, Y., Wu, X., Zhao, Z. A., & Li, F. (2024) · Biochemical Pharmacology · doi:10.1016/j.bcp.2024.116648 · Cited by 13
Wang, W., Lian, H., Liang, Y., Ye, Y., Tam, P. K. H., & Chen, Y. (2024) · Cells · doi:10.3390/cells13231997 · Cited by 13
“Its advantage lies in the fact that it outperformed a placebo at week 52 in both primary histological endpoints (NASH resolution without worsening of fibrosis, and improvement in fibrosis by ≥ 1 stage without worsening of nonalcoholic fatty liver disease (NAFLD) activity score) [4].”
Prevention of liver cancer in the era of next-generation antivirals and obesity epidemic
Suzuki, H., Fujiwara, N., Singal, A. G., Baumert, T. F., Chung, R. T., Kawaguchi, T., & Hoshida, Y. (2025) · Hepatology · doi:10.1097/hep.0000000000001227 · Cited by 18
Hirayama, K., Koshizaka, M., Ishibashi, R., Shoji, M., Horikoshi, T., Sakurai, K., Yokote, K., & PRIME‐V Study Group (2025) · Diabetes Obesity and Metabolism · doi:10.1111/dom.16198 · Cited by 15
“Although new drugs and therapies are currently being developed specifically for MASLD treatment, 31 SGLT2i may be preferred as they address some of the limitations associated with other therapies, including managing weight gain and reducing cardiovascular and renal risks without the significant…”
Hasan, A. H., Abid, M., Abid, M. H., Suhail, L., & Nazir, A. (2025) · Health Science Reports · doi:10.1002/hsr2.70394 · Cited by 13
Coyne, E. S., Nie, Y., Lee, D., Pandovski, S., Yang, T., Zhou, H. H., Rosahl, T. W., Carballo‐Jane, E., Abdurrachim, D., Zhou, Y., et al. (2025) · Hepatology Communications · doi:10.1097/hc9.0000000000000637 · Cited by 14
“[6,7,9,10] Although the recent FDA approval of the thyroid hormone beta receptor agonist, resmetirom, for the treatment of MASH is a much-needed therapeutic for patients, [11] novel therapies targeting independent and complementary pathways that can reduce liver fibrosis are still needed.”
Lin, L., Lai, J., Luo, L., Ye, J., & Zhong, B. (2025) · Annals of Hepatology · doi:10.1016/j.aohep.2025.101780 · Cited by 15
Zhang, J., Liu, X., Jin, X. J., Mao, X., Xu, X., Zhang, X., Shang, K., Xu, Y., Zhang, Y., Meng, G., et al. (2025) · Pharmacological Research · doi:10.1016/j.phrs.2025.107664 · Cited by 11
Opportunistic Screening of Chronic Liver Disease with Deep-Learning–Enhanced Echocardiography
Sahashi, Y., Vukadinovic, M., Amrollahi, F., Trivedi, H. D., Rhee, J., Chen, J. H., Cheng, S. C., Ouyang, D., & Kwan, A. C. (2025) · NEJM AI · doi:10.1056/aioa2400948 · Cited by 14
de Souza, M. H. G., Al‐Sharif, L., Diaz, I., Khalil, S. M., Lv, X., Mantovani, A., & Villela‐Nogueira, C. A. (2025) · Liver International · doi:10.1111/liv.70029 · Cited by 14
“A milestone in this journey was the US Food and Drug Administration's (FDA) conditional approval of resme-tirom for the treatment of non-cirrhotic MASH patients with moderate to advanced liver fibrosis [9].”
Patil, N. Y., Rus, I., Ampadu, F. A., Abushukair, H. M., Bonvicino, S. M., Brush, R. S., Eaton, E., Agbaga, M., Oh, T. G., Friedman, J. E., et al. (2025) · American Journal of Physiology-Gastrointestinal and Liver Physiology · doi:10.1152/ajpgi.00337.2024 · Cited by 11
Lean MASLD and Cardiovascular Disease: A Review
Lebovics, N., Heering, G., Frishman, W. H., & Lebovics, E. (2025) · Cardiology in Review · doi:10.1097/crd.0000000000000893 · Cited by 13
Shu, X., Cao, Y. J., Wu, Y., Chen, M., Zhao, W., Ji, G., & Zhang, L. R. (2025) · Journal of Ethnopharmacology · doi:10.1016/j.jep.2025.119719 · Cited by 14
Kim, D.-H., Choi, G. H., Song, E.-B., Lee, H. N., Kim, J. K., Jang, Y., Park, J., Chi, S., Han, J., Kim, D., et al. (2025) · Cell Reports Medicine · doi:10.1016/j.xcrm.2025.102047 · Cited by 12
Ability of soluble TREM2 and PRO-C3 as biomarkers to predict changes in MASLD activity
Wernberg, C. W., Chandran, V. I., Lauridsen, M. M., Skytthe, M. K., Hansen, C. D., Hansen, J. K., Grønkjær, L. L., Jacobsen, B. G., Caterino, T. D., Detlefsen, S., et al. (2025) · JHEP Reports · doi:10.1016/j.jhepr.2025.101432 · Cited by 13
The importance of patient engagement in the multimodal treatment of MASLD
Boeckmans, J., Hagström, H., Cryer, D. R. H., & Schattenberg, J. M. (2025) · Communications Medicine · doi:10.1038/s43856-025-00871-1 · Cited by 19
Self-citationThe Liver in Diabetes and Metabolic Syndrome
Mahmoud, M. C., & Abdelmalek, M. F. (2025) · Clinics in Liver Disease · doi:10.1016/j.cld.2025.04.003 · Cited by 14
Self-citationXi, J., Lei, S.-Y., Chen, J., Liu, J., Shan, C., Sun, X., Zheng, Q., & Shi, X. (2025) · Cell Death Discovery · doi:10.1038/s41420-025-02558-x · Cited by 15
Metadata
- Authors
- Harrison, S. A., Bedossa, P., Guy, C. D., Schattenberg, J. M., Loomba, R., Taub, R., Labriola, D., Moussa, S. E., Neff, G. W., Rinella, M. E., Anstee, Q. M., Abdelmalek, M. F., Younossi, Z., Baum, S. J., Francque, S., Charlton, M. R., Newsome, P. N., Lanthier, N., Schiefke, I., Mangia, A., Pericàs, J. M., Patil, R., Sanyal, A. J., Noureddin, M., Bansal, M. B., Alkhouri, N., Castera, L., Rudraraju, M., & Ratziu, V.
- Affiliations
- University Hospitals Birmingham NHS Foundation Trust (GB)
- From the University of Oxford, Oxford (S.A.H.), the Translational and Clinical Research Institute, Faculty of Medical Sciences, Newcastle University, Newcastle upon Tyne (Q.M.A.), and the National Institute for Health Research, Biomedical Research Centre at University Hospitals Birmingham NHS Foundation Trust and the University of Birmingham, Birmingham (P.N.N.) — all in the United Kingdom; Pinnacle Clinical Research, San Antonio (S.A.H., M.R.), South Texas Research Institute, Edinburg (R.P.), and Houston Methodist Hospital, Houston Research Institute, Houston (M.N.) — all in Texas; Liverpat and University of Paris (P.B.), INSERM, Unité Mixte de Recherche Scientifique (UMRS) 1139, Centre de Recherche sur l’Inflammation (L.C.), and Sorbonne Université, ICAN Institute for Cardiometabolism and Nutrition, Assistance Publique–Hôpitaux de Paris (APHP), INSERM, UMRS 1138, Centre de Recherche des Cordeliers (V.R.), Paris, and Université Paris-Cité, Department of Hepatology, Beaujon Hospital, APHP, Clichy (L.C.) — ...
- Universitat Autònoma de Barcelona (ES)
- Houston Methodist (US)
- ORCID
- Harrison, Stephen A.
- Guy, Cynthia D.
- Schattenberg, Jörn M.
- Loomba, Rohit
- Taub, Rebecca
- Neff, Guy W.
- Rinella, Mary E.
- Anstee, Quentin M.
- Abdelmalek, Manal F.
- Younossi, Zobair
- Baum, Seth J.
- Francque, Sven
- Charlton, Michael R.
- Newsome, Philip N.
- Lanthier, Nicolas
- Mangia, Alessandra
- Pericàs, Juan M.
- Patil, Rashmee
- Sanyal, Arun J.
- Noureddin, Mazen
- Bansal, Meena B.
- Alkhouri, Naim
- Rudraraju, Madhavi
- Ratziu, Vlad
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2024-02-08
- Volume
- 390
- Issue
- 6
- Pages
- 497-509
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W4391592880
- Cited by
- 2,084
- References
- 26
- Citations by year
- 2026: 797 · 2025: 807 · 2024: 478
- FWCI
- 635.31
- Type
- journal article
- Language
- en
- Open access
- Licence
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- University of Birmingham Research Portal (University of Birmingham) (publishedVersion, other-oa)
- IRIS Research product catalog (Sapienza University of Rome) (submittedVersion, other-oa)
- HAL (submittedVersion)
- Digital Access to Libraries (submittedVersion, other-oa)
- Digital Access to Libraries (submittedVersion)
- VUBIR (Vrije Universiteit Brussel) (submittedVersion)
- Open Access CRIS of the University of Bern
- Funders
- Madrigal Pharmaceuticals
- Topics
- Health Sciences › Medicine › Hepatology › Liver Disease Diagnosis and Treatment
- Health Sciences › Medicine › Hepatology › Liver physiology and pathology
- Health Sciences › Medicine › Hepatology › Liver Diseases and Immunity
- Keywords
- resmetirom, nonalcoholic steatohepatitis, liver fibrosis, thyroid hormone receptor beta agonist, NASH resolution, fibrosis regression, NAFLD activity score, LDL cholesterol, triglycerides, cirrhosis prevention, drug safety and tolerability
- MeSH terms
- Adult, Biopsy, Dose-Response Relationship, Drug, Double-Blind Method, Humans, Liver, Liver Cirrhosis, Pyridazines, Uracil, Treatment Outcome, Thyroid Hormone Receptors beta, Non-alcoholic Fatty Liver Disease
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.